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Summary Semen analysis was performed in 14 men a median of 13.5 months after completion of VAPEC-B
chemotherapy for Hodgkin's disease or non-Hodgkin's lymphoma. Semen from 12 patients contained motile
spermatozoa, and in nine cases the count was >20 million ml'. One patient was azoospermic (VAPEC-B
followed by pelvic radiotherapy) and another had a count of 21 millionml1' but sperm were non-motile.
These findings suggest that, in the majority of cases, VAPEC-B chemotherapy does not cause permanent
damage to the male germinal epithelium. A more detailed study of gonadal function in males and females
before and after treatment with VAPEC-B for Hodgkin's disease is currently in progress.
VAPEC-B, a cytotoxic regimen comprising myelosuppressive
(doxorubicin plus cyclophosphamide or etoposide) and
relatively non-myelosuppressive drugs (vincristine and
bleomycin) administered on an alternate-week basis for 11
weeks (Figure 1), has been used at this institute for remission
induction in high-grade non-Hodgkin's lymphoma (NHL) since
1987. Results in 184 patients treated at the Christie Hospital,
Manchester, and St Bartholomew's Hospital, London, have
recently been reported (Radford et al., 1993).
VAPEC-B has also been used for treating Hodgkin's
disease (HD) in patients relapsing after previous
chemotherapy. In a pilot study involving 20 patients, 14
responded (complete remission, 10; partial remission, 4) after
a median 6 weeks of treatment (Radford & Crowther, 1991).
In view of these promising results it was decided to test
VAPEC-B in newly diagnosed HD, and a randomised trial
for patients with low-risk, stage I or II disease (no B symp-
toms or mediastinal bulk) was activated by the Manchester
Lymphoma Group in 1989.
Many patients develop HD as young adults, and the
impact of treatment on gonadal function is therefore of
particular importance for these individuals. Following con-
ventional MOPP-like combinations, azoospermia is inevitable
in males (Chapman et al., 1979; Whitehead et al., 1982). A
pilot study to investigate fertility in men treated with
VAPEC-B chemotherapy was therefore undertaken.
Patients and methods
At the time of study a total of 133 patients had received
VAPEC-B chemotherapy at the Christie Hospital for newly
diagnosed HD (n = 22) or NHL (n = 111). All had been
treated within the confines of a clinical trial protocol.
Seventy-two were male, and of these 27 were alive, disease-
free and had not received additional chemotherapy for any
reason. Within this group, three patients had undergone
vasectomy, and two were considered unsuitable on the
grounds of advanced age and psychiatric illness. Thus, 22
patients were eligible for the study but eight declined to take
part, leaving 14 (HD, n = 7; NHL, n = 7) who consented to
semen analysis.
Microscopy was performed on a semen sample obtained by
masturbation and the sperm count and motility recorded.
Age, treatment received (including radiotherapy fields where
appropriate), time lapse since completion of VAPEC-B
chemotherapy and any subsequent pregnancies in a female
partner were also noted. Results of pretreatment semen
analysis were available in four patients (nos. 5, 7, 11, 13) in
whom semen had been cryopreserved before starting
chemotherapy.
Results
The median age for all 14 patients at the start of
chemotherapy was 29.5 years (range 16-45) with a median
time lapse since completion of chemotherapy of 13.5 months
(range 5-30 months). In general, patients treated for NHL
had a longer treatment-free period before semen analysis
(median 20 months) than those treated for HD (median 8
months). All but one patient had received radiotherapy in
addition to VAPEC-B, and in two cases (patients 5 and 10)
the radiation field included part of the pelvis. Individual
patient characteristics are shown in Table I.
Semen from 12 patients was found to contain motile sper-
matozoa, and in nine cases the count was >20 x 106 ml'
(Table I). There was no significant difference in sperm counts
between men treated with 4 or 11 weeks of VAPEC-B (medi-
ans 61 x 106 ml-' and 107 x 106 mlh ' respectively).
Patient 5, who had received 4 weeks of VAPEC-B followed
by radiation to the right lower abdomen and pelvis, was
azoospermic (pretreatment count of 15 x 106 ml-'), and
patient 14 had a count of 21 x 106ml-' but sperm were
non-motile, possibly because of a delay in analysis (semen
sample produced at home). Patient 10, who underwent
radiotherapy to the right side of pelvis on completion of
chemotherapy, had a count of 14 x 106 ml-' and was
therefore oligospermic (<20 x 106 ml-') by WHO (1980)
criteria. This patient was oligospermic before starting treat-
ment (count 15 x 106 ml-'), but his wife conceived 8 months
after the completion of VAPEC-B and has since delivered a
healthy infant. Patients and 4, neither of whom had
received radiotherapy to sites below the diaphragm, were also
oligospermic with counts of 15 and 4 x 106 ml-' respectively.
Unfortunately, pretreatment semen analysis had not been
performed in these patients.
Discussion
The introduction of MOPP chemotherapy in the early 1960s
proved to be a turning point in the treatment of advanced
HD (De Vita et al., 1970). Before that time the prospects for
long-term survival were poor and concerns over the late
effects of cytotoxic drugs on normal tissues were largely
irrelevant. However, most patients treated with MOPP and
its derivative MVPP (Nicholson et al., 1970) were found to
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Table I Sperm counts in 14 patients after VAPEC-B chemotherapy for Hodgkin's disease (HD) or non-Hodgkin's
lymphoma (NHL)
Spermatozoa
Months since (millionsml-')
Patient Age Weeks completion of (pretreatment
no. (years) Diagnosis VAPEC-B Radiotherapy VAPEC-B value)
1 44 HD 4 Right axilla 10 15
2 36 HD 4 Mantle 15 61
3 31 HD 4 Head and neck 18 215
4 40 HD 4 Head and neck 5 4
5 19 HD 4 Right lower abdomen and 7 0 (15)
right pelvis
6 31 HD 4 Mantle 8 155
7 25 HD 4 Head and neck 6 123 (250)
8 16 NHL 11 Anterior chest wall 30 107
9 45 NHL 11 Left neck 12 95
loa 24 NHL 11 Right pelvis 10 14 (15)
11 28 NHL 11 Mediastinum 26 80
12 37 NHL 11 - 22 209
13 18 NHL 11 Right neck 20 280 (290)
14 22 NHL 11 Head and neck 20 2lb
aThis patient's wife conceived 8 months after completing VAPEC-B. bSpermatozoa were non-motile.
enter remission and, although 30-40% subsequently re-
lapsed, it was evident that advanced HD was potentially
curable using combination chemotherapy. In these circum-
stances, the long-term effects of treatment on normal tissues
are of great importance. This is particularly true of gonadal
function in patients with HD, which commonly affects young
people who may not have started or completed a family
when the diagnosis is made.
Both MOPP and MVPP were found to produce a very
high incidence of azoospermia, with only a few men recover-
ing spermatogenesis after treatment (Chapman et al., 1979;
Whitehead et al., 1982). Procarbazine, a component of both
regimens, causes complete aplasia of the germinal epithelium
in the rat (Jackson et al., 1961) and the non-human primate
(Sieber et al., 1978), and mustine and vinblastine are also
implicated in the germinal epithelial damage following
MOPP/MVPP (Spitz, 1948; Vilar, 1975). Of these, only vin-
blastine is included in the ABVD regimen, which is reported
as causing no permanent gonadal damage. Nevertheless, 13
of 24 patients treated with ABVD were found to be azoosper-
mic (n = 8) or oligospermic (n = 5) a median of 10 months
after completion ofchemotherapy, and although full recovery
of spermatogenesis occurred in all these patients this was not
until a further 18 months (median 10 months) had elapsed
(Viviani et al., 1985). Furthermore, ABVD is commonly used
in combination with MOPP, either as alternating cycles of
each regimen (Canellos et al., 1992) or as 'hybridised' cycles
of MOPP/ABVD (Viviani et al., 1991), and it seems likely
that these treatments cause more severe damage to the ger-
minal epithelium than ABVD alone.
In the present study, only 1 of 14 patients was azoospermic
a median of 13.5 months after VAPEC-B. He was oligosper-
mic before starting treatment and had received pelvic irradia-
tion following chemotherapy. A further three men were
Weeks
1 Doxorubicin 35 mgm2 i.v. Prednisolone
Cyclophosphamide 350 mg m-2 i.v. 50 mg p.o. daily
2 Vincristine 1.4 mg mr2 i.v.
Bleomycin 10mgm2 i.v.
3 Doxorubicin 35 mg m-2 i.v.
Etoposide 100mgM-2 p.o. daily
for 5 days
4 Vincristine 1.4 mgM-2 i.v.
Bleomycin 10mgm iv.
Figure 1 The first 4 weeks of VAPEC-B chemotherapy are
shown. Subsequent weeks of treatment (to week 11) are repeats
of this same basic pattern. In addition to the cytotoxic drugs and
prednisolone, prophylactic co-trimoxazole 960 mg twice daily and
ketoconazole 200 mg twice daily are prescribed for the duration
of treatment.
oligospermic post treatment, and one of these (patient 10)
was known to have a subnormal sperm count before starting
chemotherapy. All the others (n = 10) had counts greater than
20 x 106 ml-', although spermatozoa from patient 14 were
non-motile, possibly because of some delay in analysis.
These results suggest that treatment with VAPEC-B does
not cause permanent damage to the male germinal epi-
thelium. On this basis, full assessment of gonadal function is
now being performed before and after chemotherapy in a
cohort of males and females receiving 11 weeks of VAPEC-B
for advanced Hodgkin's disease. However, until the results of
this prospective study are available, all male patients will
continue to be offered semen cryopreservation before starting
treatment.
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